Sevirumab

Drug Profile

Sevirumab

Alternative Names: EV2 7; MSL 109; Protovir; SDZ MSL 109

Latest Information Update: 22 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; PDL BioPharma
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 22 Jul 2016 Changed the NDR date to 2007 because NCT00002016 was completed in 2005
  • 23 Jun 2007 No-Development-Reported for Cytomegalovirus infections in USA (IV) (NCT00002016)
  • 17 May 2001 No-Development-Reported for Cytomegalovirus infections in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top